85 related articles for article (PubMed ID: 8938148)
1. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells.
Batra S; Karlsson R; Witt L
Int J Cancer; 1996 Nov; 68(5):644-9. PubMed ID: 8938148
[TBL] [Abstract][Full Text] [Related]
2. Binding of vinblastine and estramustine to isolated plasma membrane fractions from human prostate and prostatic tumors.
Batra S; Larsson I
Cancer Lett; 1996 Sep; 106(2):217-20. PubMed ID: 8844975
[TBL] [Abstract][Full Text] [Related]
3. Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.
Mareel MM; Storme GA; Dragonetti CH; De Bruyne GK; Hartley-Asp B; Segers JL; Rabaey ML
Cancer Res; 1988 Apr; 48(7):1842-9. PubMed ID: 3349462
[TBL] [Abstract][Full Text] [Related]
4. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
5. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
6. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Speicher LA; Barone L; Tew KD
Cancer Res; 1992 Aug; 52(16):4433-40. PubMed ID: 1353706
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
Awakura Y; Yamamoto M; Fukuzawa S; Itoh N; Nonomura M; Fukuyama T
Hinyokika Kiyo; 2000 Jul; 46(7):449-52. PubMed ID: 10965448
[TBL] [Abstract][Full Text] [Related]
8. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
9. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine.
Essand M; Nilsson S; Carlsson J
Anticancer Res; 1993; 13(5A):1261-8. PubMed ID: 8239495
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of prostate cancer growth by estramustine and colchicine.
Fakih M; Yagoda A; Replogle T; Lehr JE; Pienta KJ
Prostate; 1995 Jun; 26(6):310-5. PubMed ID: 7784270
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
12. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
13. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
Kreis W; Budman DR; Calabro A
Br J Urol; 1997 Feb; 79(2):196-202. PubMed ID: 9052470
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
16. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent interaction between vinblastine and cisplatin in Ehrlich ascites tumors in mice.
Cemazar M; Auersperg M; Scancar J; Kirbis IS; Pogacnik A; Sersa G
J Pharmacol Exp Ther; 2002 Jul; 302(1):337-43. PubMed ID: 12065735
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
[TBL] [Abstract][Full Text] [Related]
19. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance.
Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR
Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
Naik H; Lehr JE; Pienta KJ
Urology; 1996 Sep; 48(3):508-11. PubMed ID: 8804514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
